Krasinskas AM. Cholangiocarcinoma. Surg Pathol Clin. 2018;11:403–29.

Article  PubMed  Google Scholar 

Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma. Pathologica. 2021;113:158–69.

Article  PubMed  PubMed Central  Google Scholar 

John ES, Tarnasky PR, Kedia P. Ablative therapies of the biliary tree. Transl Gastroenterol Hepatol. 2021;6:63.

Article  PubMed  PubMed Central  Google Scholar 

Ben Khaled N, Jacob S, Rossler D, et al. Current state of multidisciplinary treatment in cholangiocarcinoma. Dig Dis. 2021.

Acquisto S, Iyer R, Rosati LM, et al. Cholangiocarcinoma: treatment, outcomes, and nutrition overview for oncology nurses. Clin J Oncol Nurs. 2018;22:E97–102.

Article  PubMed  Google Scholar 

Zhou CJ, Wang DH, Kong XW, et al. Protein regulator of cytokinesis 1 regulates chromosome dynamics and cytoplasmic division during mouse oocyte meiotic maturation and early embryonic development. FEBS J. 2020;287:5130–47.

Article  CAS  PubMed  Google Scholar 

Jiang W, Jimenez G, Wells NJ, et al. PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell. 1998;2:877–85.

Article  CAS  PubMed  Google Scholar 

Li J, Dallmayer M, Kirchner T, Musa J, Grunewald TGP. PRC1: linking cytokinesis, chromosomal instability, and cancer evolution. Trends Cancer. 2018;4:59–73.

Article  CAS  PubMed  Google Scholar 

Hanicinec V, Brynychova V, Rosendorf J, et al. Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer. Oncol Lett. 2021;22:598.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bu H, Li Y, Jin C, et al. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer. Int J Oncol. 2020;56:685–96.

CAS  PubMed  PubMed Central  Google Scholar 

Liang Z, Li X, Chen J, et al. PRC1 promotes cell proliferation and cell cycle progression by regulating p21/p27-pRB family molecules and FAK-paxillin pathway in non-small cell lung cancer. Transl Cancer Res. 2019;8:2059–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Li J, Xu L, et al. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1. J Exp Clin Cancer Res. 2022;41:149.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77:849–64.

Article  CAS  PubMed  Google Scholar 

Lu S, Ke S, Wang C, et al. NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. 2022; 11:39.

Jia M, Yang F, Xu Y, et al. Baicalin induced apoptosis of human cholangiocarcinoma cell through activating AMPK/mTORC1/p70S6K signaling pathway. Bull Exp Biol Med. 2022;173:366–70.

Article  CAS  PubMed  Google Scholar 

Lu X, Peng B, Chen G, et al. YAP accelerates notch-driven cholangiocarcinogenesis via mTORC1 in mice. Am J Pathol. 2021;191:1651–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Yu C, Luo Y, et al. Aldolase A enhances intrahepatic cholangiocarcinoma proliferation and invasion through promoting glycolysis. Int J Biol Sci. 2021;17:1782–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujinaga A, Hirashita T, Hirashita Y, et al. Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma. BMC Gastroenterol. 2023;23:157.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31.

Article  PubMed  Google Scholar 

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165–71.

Article  CAS  PubMed  Google Scholar 

Jensen LH, Lindebjerg J, Ploen J, Hansen TF, Jakobsen A. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol. 2012;23:2341–6.

Article  CAS  PubMed  Google Scholar 

Zhang B, Shi X, Xu G, et al. Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner. J Cell Mol Med. 2017;21:1329–41.

Article  PubMed  PubMed Central  Google Scholar 

Li H, Long J, Xie F, et al. Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma. Oncol Rep. 2019;42:1833–42.

CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Lu S, Chen Y, He H, Lu W, Lin K. Analysis of transcriptome in the relationship between expression of PRC1 protein and prognosis of patients with cholangiocarcinoma. J Int Med Res. 2021;49:300060521989200.

CAS  PubMed  Google Scholar 

Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257–74.

Article  CAS  PubMed  Google Scholar 

Li M, Yang J, Zhou W, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117:974–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Xu D, Li H, et al. Avasimibe dampens cholangiocarcinoma progression by inhibiting FoxM1-AKR1C1 signaling. Front Oncol. 2021;11:677678.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y. TESC promotes TGF-alpha/EGFR-FOXM1-mediated tumor progression in cholangiocarcinoma. Cancers (Basel). 2020; 12.

Klinhom-On N, Seubwai W, Sawanyawisuth K, et al. FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients. Heliyon. 2021;7:e06846.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pant K, Richard S, Peixoto E, Gradilone SA. Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. Front Med (Lausanne). 2020;7:113.

Article  PubMed  Google Scholar 

Thonsri U, Seubwai W, Waraasawapati S, et al. Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. Histol Histopathol. 2017;32:503–10.

CAS  PubMed  Google Scholar 

Ma P, Xing M, Han L, et al. High PD-L1 expression drives glycolysis via an Akt/mTOR/HIF-1α axis in acute myeloid leukemia. Oncol Rep. 2020;43:999–1009.

CAS  PubMed  Google Scholar 

Yan X, Yang C, Hu W, et al. Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1α pathway. Oncol Rep. 2020;44:103–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan Z, Zheng W, Li H, et al. LOXL2 upregulates hypoxia-inducible factor-1α signaling through Snail-FBP1 axis in hepatocellular carcinoma cells. Oncol Rep. 2020;43:1641–9.

CAS  PubMed  PubMed Central  Google Scholar 

Cheng H, Hao Y, Gao Y, et al. PLCε promotes urinary bladder cancer cells proliferation through STAT3/LDHA pathway-mediated glycolysis. Oncol Rep. 2019;41:2844–54.

CAS  PubMed  PubMed Central  Google Scholar 

Shi J, Ye J, Fei H, et al. YWHAZ promotes ovarian cancer metastasis by modulating glycolysis. Oncol Rep. 2019;41:1101–12.

CAS  PubMed  Google Scholar 

Xu L, Li Y, Zhou L, et al. SIRT3 elicited an anti-Warburg effect through HIF1alpha/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis. Cancer Med. 2019;8:2380–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong ZF, Zhang WQ, Wang SJ, et al. Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma. Biomed Pharmacother. 2020;123:109766.

Article  CAS  PubMed  Google Scholar 

Joechle K, Jumaa H, Thriene K, et al. Dual inhibition of mTORC1/2 reduces migration of cholangiocarcinoma cells by regulation of matrix metalloproteinases. Front Cell Dev Biol. 2021;9:785979.

Article  PubMed  Google Scholar 

Cui XD, Lee MJ, Kim JH, et al. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology. 2013;57:2248–60.

Article  CAS